Caribou cuts pipeline and workforce to focus on lead CAR-T programmes
Caribou Biosciences is narrowing its pipeline and reducing its workforce by approximately 32% amid continued challenges in the cell and …
Post
-
-
Granite Bio secures $100m in funding for new antibodies
Swiss-based immunology company Granite Bio has secured $100m in funding for its new antibody treatments that target several autoimmune diseases. This …
-
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy
The European Commission (EC) has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD). This designation …
-
Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds
The top 20 biopharmaceutical companies demonstrated a strong start to 2025, despite ongoing uncertainty surrounding the potential impact of President …
-
MSD’s Gardasil sales slide further due to China constraints
A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus …
-
MSD’s Gardasil sales slide further due to China constraints
A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus …
-
Challenges in filling for alum drug products: What does a CDMO need to successfully fill alum drug products?
What are Alum Products, and why are they challenging to fill? Alum products, commonly referring to aluminum-based adjuvants, play a vital …
-
Thermo Fisher counters tariffs with $2bn investment into US manufacturing
Thermo Fisher has outlaid $2bn to expand manufacturing and development in the US, joining the long list of companies directing …
-
Pharma companies in Europe push for US-level drug prices
Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US, as reported by …
-
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to …
-
Repertoire and Genentech to develop autoimmune disease therapies
Repertoire Immune Medicines has signed a partnership and licensing agreement with Roche’s Genentech, focusing on the discovery and development of …
-
Biogen’s Friedreich’s ataxia treatment authorised in UK
Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Skyclarys (omaveloxolone) …
-
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide, …
-
Veraxa to go public in $1.6bn SPAC deal with Voyager
Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, …
-
Synthetic hormones and the future of contraception
The landscape of contraception for women has seen minimal change over the past 50 years, with successive generations often relying …
